In this research, we revealed that AS-IV elevated the expression of PHD2 to alleviate PAH progression through inhibiting HIF1α and NLRP3 inflammasome, which was not clarified in the previous publications. This evidence concerns the gene HIF1A and pulmonary arterial hypertension.